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 Human epididymis protein 4 (HE4) was firstly identified in epididymal epithelial cells and described as a protease inhibitor 
playing a role in spermatogenesis. Regarding numerous studies proving its diverse potential as a prognostic and predictive 
factor in ovarian cancer, it was incorporated into ROMA algorithm. Nevertheless, recent studies have shown that serum 
level of HE4 is not exclusive to ovarian cancer. As a result, doctors using ROMA algorithm for stratifying patients with ovarian 
cancer must be aware of other conditions that may affect serum level of HE4. This review comprises different conditions 
connected with high level of HE4 that might impact ovarian cancer diagnosing process. Moreover, discovering increased 
HE4 level in various conditions should open discussion about its applicability in diseases other than ovarian cancer. 
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Introduction
Human epididymis protein 4 (HE4) was firstly identified in epi-
didymal epithelial cells and described as a protease inhibitor 
playing role in spermatogenesis. It is encoded by WAP 4-disulfi-
de core domain 2 (WFDC2) [1]. Selective overexpression of HE4 
has a well-established role in ovarian cancer tumorigenesis, 
but little is known about its possible role in other conditions 
[2]. Regarding numerous studies proving its diverse potential 
as a prognostic and predictive factor in ovarian cancer, it was 
incorporated into ROMA algorithm, that is a quantitative test 
based on the serum level of HE4, CA125, and combined with 
menopausal status [1]. Using this algorithm allows for stratify-
ing patients into two groups – in a high or low ovarian cancer 
risk and as a result avoiding unnecessary surgeries [3, 4]. 
On the other hand, recent studies have shown that serum 
level of HE4 is not exclusive to ovarian cancer [5–8]. Described 
conditions comprise both cancer and other diseases. The most 
numerous group of researches about HE4 as a possible new 
biomarker is connected with lung cancer, especially non-small 
cell lung cancer (NSCLC) [9, 10]. Some authors even suggest 
that HE4 secretion might play an extensive role in NSCLC 
progression, like in ovarian cancer [7]. Another conditions 
suggested to be connected with HE4 comprise chronic kidney 
disease [5], renal fibrosis [11], cancers of intestinal tract [6, 12, 
13], breast cancer [8] and heart failure [14].
Due to the fact that, as mentioned above, the increased 
level of HE4 is detectable not only in patients with ovarian 
cancer, but also in patients with other diseases, doctors using 
ROMA algorithm for stratifying patients with ovarian cancer 
must be aware of other conditions that may affect the se-
rum level of HE4. The main aim of this review was to gather 
and discuss diseases connected with HE4, described in the 
literature. According to our best knowledge, a similar review 
encompassing different possible directions in HE4 usage have 
not been published yet. 
Kidney 
HE4 was proven to be expressed in the distal convoluted 
tubules of the kidney [15] and since then scientists try to find 
out correlation between its expression and the occurrence 
of chosen conditions. Chronic kidney disease (CKD) is told 
to become a worldwide public health problem with mean 
global prevalence at 13.4%. Owing to the fact that detecting 
CKD at early stages allows its appropriate management there 
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is an ongoing need for searching new diagnostic indicators 
[16]. One of the most recently suggested is HE4. In the study 
conducted by Yuan et al. (2017) [5] serum level of HE4 increased 
significantly with renal function decline and was proven to 
achieve better diagnostic ability, sensitivity and specificity than 
other laboratory indicators, so as a result, it was suggested as 
the strongest predictor for CKD. What is more, increased levels 
of HE4 were detectable even at early stages of CKD. HE4 level 
in blood samples derived from patients with renal disfunc-
tion was positively correlated with level of creatinine, urea 
and cystatin C as far as acute and chronic renal dysfunctions 
are concerned and has higher diagnostic value with 100% 
specificity and sensitivity [17]. On the other hand, various 
studies proved inverse correlation between HE4 and eGFR 
with statistical significance [11, 17].
The most common final pathological way of CKD is renal 
fibrosis. HE4 has been recently reported as one of the mediators 
of this phenomenon because of inhibiting the degradation of 
type I collagen [18]. In the study conducted by Wan et al. (2016) 
[11] higher levels of HE4 were detected in patients with more 
severe renal fibrosis and significant correlation between HE4 
and degree of renal fibrosis was observed. ROC curve analysis 
pointed out HE4 as a suitable biomarker for the diagnosis of 
renal fibrosis. Moreover, HE4 is suggested as a biomarker for 
predicting renal fibrosis in kidney transplant recipients due 
to its increased level and correlation with the severity of the 
disease [19].
Lupus nephritis (LN) is a common manifestation of systemic 
lupus erythematosus (SLE) and a major cause of morbidity and 
mortality in these patients. Increased serum HE4 level was pro-
ved to be associated with development of LN in SLE patients 
in two independent studies [20, 21]. However, detailed me-
chanism leading to development of LN with HE4 contribution 
remains unclear and needs further research.
Intestinal tract 
Gastric cancer (GC), despite its decreasing incidence ratio, has 
still low 5-year survival rate, thus needs factors indicating its 
prognosis and improving treatment [22]. The first investigation 
concerning HE4 expression in GC was performed by Guo et 
al. (2015) [6]. They discovered upregulation of this glycopro-
tein in gastric cancer tissues and significant correlation with 
Lauren classification, TNM stage and tumor size. Silencing HE4 
inhibited proliferation, migration and enhanced apoptosis in 
studied tissues. Regarding these discoveries, HE4 might play 
an important role in progression of GC and become a new 
target for treatment. Another aspect of HE4 in GC concerns 
sensitivity to radiotherapy. Peng et al. (2019) [23] pointed out 
hypoxia-induced upregulation of HE4 as a reason for resistance 
to radiotherapy due to the fact that stable knockdown of HE4 
sensitized cancer cells and xenograft tumors to radiotherapy. 
As a conclusion, radiotherapy connected with HE4 knockdown 
might become a potential therapeutic aim in GC. 
Next example of association between resistance to radio-
therapy and expression of HE4 is colorectal cancer (CRC). Shi et 
al. (2018) [12] demonstrated that WFDC2 deficiency improved 
the radiation resistance in CRC. miR-149 – a small noncoding 
RNA regulating post-transcriptional gene expression was pro-
ved to inhibit HE4 expression in CRC cells and sensitize CRC 
to radiation both in vivo and in vitro. As a result, exogenous 
administration of miR-149 mimic combined with radiotherapy 
might become a new therapeutic promise in CRC. In 2017, 
Kemal et al. [24] detected high level of HE4 in CRC samples 
in comparison to healthy controls. They also proposed a HE4 
as a new biomarker for stage III–IV CRC due to its significantly 
positive expression especially in this group. However, the study 
group was relatively small and without any follow-up informa-
tion. What is more, CRC seems to present wide range of tumor 
markers used for diagnosing and staging thus searching new 
biomarkers might be questioned. 
HE4 expression was suggested as a marker of early stage 
of pancreatic adenocarcinoma. In the study by Huang et al. 
(2015) [13] serum HE4 levels reached sensitivity of 45.9% and 
specificity of 93.6% with cutoff set at 4.59 ng/mL. Interestingly, 
combination of HE4 with CA19-9 increased sensitivity to 83.3% 
and the combined HE4 and CA15-3 to sensitivity of 87.5% thus 
set consisting of HE4, CA19-9 and CA15-3 might become a new 
powerful biomarker panel for early detection of pancreatic 
adenocarcinoma and diagnostic improvement. Lu et al. (2016) 
[25] research determined that treatment of recombinant HE4 
on pancreatic cancer Suit-2 cell caused significant cells growth, 
increased DNA synthesis and cell viability in comparison to 
control group without HE4 treatment. Moreover, treatment 
with HE4 upregulated PCNA (key molecule for DNA synthe-
sis) and downregulated p21 (a critical cell cycle regulator). To 
conclude, HE4 presents an undeniable role in pancreatic cancer 
development and might be used as a potential biomarker in 
its early stage detection. 
Lung cancer
Owing to the fact that lung cancer is still a leading cause of 
cancer morbidity and mortality all over the world, accurate 
and early diagnostic tools encompassing this malignancy are 
in the area of scientists’ interest [22]. Serum HE4 levels were 
proven to be significantly higher in NSCLC patients than in 
benign lung diseases and healthy controls. What is more, its 
higher level was correlated with high TNM stage, positive 
lymph nodes metastasis and weight loss [7, 26]. Connecting 
these facts with documented shorter overall survival (OS) in 
the group with higher level of HE4 allows us to conclude 
that serum levels of HE4 might predict poor prognosis in 
NSCLC patients. Moreover, Mo et al. (2018) [26] observed that 
HE4 was a satisfying discriminator of lung adenocarcinoma. 
Although Celik et al. (2017) [27] doubted the reliability of 
HE4 as a lung cancer biomarker, they admitted that it was a 
promising candidate for adenocarcinoma treatment. On the 
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other hand, Korkmaz et al.  (2018) [28] suggested a panel of 
three tumor markers including HE4 for discriminating lung 
cancer from benign lung lesions and subtyping as small cell 
lung cancer (SCLC). 
Survivors of lung cancer are at high risk of disease recur-
rence, thus we are in a need of sensitive methods for their 
postoperative monitoring. Current monitoring system is based 
on clinical examination and imaging methods. However, this 
combination might in some cases turn out to be insufficient. 
Muley et al. (2019) [29] suggested algorithm of serial serum 
measurements consisting of HE4 and another biomarker – 
CYFRA 21-1 for a recurrence detection. Their suggestion was 
based on the observation of 31 out of 115 patients suffering 
from adenocarcinoma recurrence – serum levels of CYFRA 
21-2 and HE4 were significantly higher in samples taken from 
patients with recurrence in comparison to these derived from 
patients in remission. 
Breast cancer 
Breast cancer (BC) is the most commonly diagnosed cancer 
among women all over the world [22]. Regarding to this fact, 
contemporary science tries to find out new markers for more 
effective diagnosis and treatment because the sensitivity and 
specificity of known biomarkers such as CA15-3 and CEA are 
rather low [30]. Gunduz et al. (2016) [8] identified a significant 
elevation of serum HE4 in comparison to healthy control group 
and a correlation between the levels of HE4 and CA15-3 in 
patients suffering from BC. On the basis of these results they 
proposed HE4 as a potential biomarker for BC. Nevertheless, 
the presented study was conducted on a small group of pa-
tients and authors did not achieve any significant results as 
far as many well-known clinicopathological factors in BC are 
concerned, thus it seems to be too early to call a HE4 a po-
tential biomarker in this condition. In recent years miRNA has 
become a new target in cancer research due to its correlation 
with prognosis, clinical staging and metastases [31]. Lu et al. 
(2017) [32] decided to combine plasma miR-127-3p and HE4 
in BC analysis. They concluded that levels of both plasma 
miR-127-3p and HE4 were increased in BC and combined 
detection greatly improved methods of early diagnosis of BC 
with sensitivity of 87.4%
Heart failure
Although new research suggests HE4 as a potential novel bio-
marker for heart failure (HF), some obstacles may complicate 
its usage in monitoring of these patients [33]. Most of them are 
mentioned above – increased level of HE4 is detectable not 
only in patients with HF, but also in patients with ovarian cancer 
[2], CKD [5] or pancreatic adenocarcinoma [13]. However, HE4 
as a part of multi-marker model, might be a potential aim in 
the HF stratification [33]. In the study conducted among 567 
patients with HF, those with higher HE4 serum level had an 
unfavorable clinic profile comprising older age, higher NYHA 
class, greater number of comorbidities such as atrial fibrillation. 
Plasma HE4 levels were correlated with numerous HF plasma 
markers (including NT-proBNP, BNP and galectine-3) with the 
strongest correlation including GDF15 – an emerging prognostic 
biomarker of cardiovascular diseases [34]. Similar results were 
achieved by Piek et al. (2017) [14] – strong correlation especially 
comprising HF severity based on NYHA and NT-proBNP levels 
was detected. Levels of HE4 was also correlated with risk factors 
including age, male sex, hypertension and diabetes. What is 
more, patients with HE4 levels above the median had worse 
survival rate. Nevertheless, the study was conducted on a rela-
tively small sample size and, as mentioned above, using HE4 as 
a marker for HF diagnosing and risk stratification might turn out 
to be impossible due to frequent coincidence between HF and 
other conditions which makes HE4 non-specific.
Conclusions 
HE4 is not exclusive for ovarian cancer. In recent studies 
it was proven to have a possible role in diagnosing other 
conditions, including cancers. Nevertheless, the connection 
between its biology, genetics and pathological condition 
remains unclear. The most important conclusion from this 
review suggests carefulness while using HE4 in ovarian can-
cer diagnosing and remembrance about other conditions 
that might affect our judgement. Furthermore, owing to 
developing branch of using HE4 in other diseases we mi-
ght ask ourselves the question about its applicability in yet 
unknown syndromes. 
Conflict of interests: none declared
Marta Maksimiuk
Medical University of Warsaw
Department of Cancer Prevention
Students’ Scientific Organization of Cancer Cell Biology 
ul. Żwirki i Wigury 81 
02-091 Warszawa, Poland
e-mail: marcioszka.m@gmail.com
Received: 4 Jun 2019 
Accepted: 22 Jul 2019
References
1. Chudecka-Glaz AM. ROMA, an algorithm for ovarian cancer. Clin Chim 
Acta. 2015; 440: 143–151. 
2. Moore RG, Hill EK, Horan T et al. HE4 (WFDC2) gene overexpression 
promotes ovarian tumor growth. Sci Rep. 2014; 4: 3574. 
3. Wei SU, Li H, Zhang B. The diagnostic value of serum HE4 and CA-125 
and ROMA index in ovarian cancer. Biomed Rep. 2016; 5 (1): 41–44. 
4. Li QL, Wang CJ, Qi P et al. Correlation of preoperative ROMA scores with 
clinical stage in epithelial ovarian cancer patients. Clin Transl Oncol. 
2017; 19 (10): 1260–1267. 
5. Yuan T, Li Y. Human epididymis protein 4 as a potential biomarker of 
vhronic kidney disease in female patients with normal ovarian function. 
Lab Med. 2017; 48 (3):2 38–243. 
6. Guo YD, Wang JH, Lu H et al. The human epididymis protein 4 acts as a 
prognostic factor and promotes progression of gastric cancer. Tumour 
Biol. 2015; 36 (4): 2457–2464. 
7. Lamy PJ, Plassot C, Pujol JL. Serum HE4: an independent prognostic 
factor in non-small cell lung cancer. PLoS One. 2015; 10 (6): e0128836. 
145
8. Gunduz UR, Gunaldi M, Isiksacan N et al. A new marker for breast cancer 
diagnosis, human epididymis protein 4: A preliminary study. Mol Clin 
Oncol. 2016; 5 (2): 355–360. 
9. Zhong H, Qian Y, Fang S et al. HE4 expression in lung cancer, a meta-
-analysis. Clin Chim Acta. 2017; 470: 109–114. 
10. Cheng D, Sun Y, He H. The diagnostic accuracy of HE4 in lung cancer: 
a meta-analysis. Dis Markers. 2015; 2015: 352670. 
11. Wan J, Wang Y, Cai G et al. Elevated serum concentrations of HE4 as a 
novel biomarker of disease severity and renal fibrosis in kidney disease. 
Oncotarget. 2016; 7 (42): 67748–67759. 
12. Shi LP, Guo HL, Su YB et al. MicroRNA-149 sensitizes colorectal cancer 
to radiotherapy by downregulating human epididymis protein 4. Am 
J Cancer Res. 2018; 8 (1): 30–38. 
13. Huang T, Jiang SW, Qin L et al. Expression and diagnostic value of HE4 
in pancreatic adenocarcinoma. Int J Mol Sci. 2015; 16 (2): 2956–2970.
14. Piek A, Meijers WC, Schroten NF et al. HE4 serum levels are associated 
with heart failure severity in patients with chronic heart failure. J Card 
Fail. 2017; 23 (1): 12–19. 
15. Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of 
HE4 expression in normal and malignant human tissues. Mod Pathol. 
2006; 19 (6): 847–853. 
16. Girndt M. [Diagnosis and treatment of chronic kidney disease]. Internist 
(Berl). 2017; 58 (3): 243–256. 
17. Wang L, Sun Y, Cai X et al. The diagnostic value of human epididymis 
protein 4 as a novel biomarker in patients with renal dysfunction. Int 
Urol Nephrol. 2018; 50 (11): 2043–2048. 
18. Chen P, Yang Q, Li X et al. Potential association between elevated serum 
human epididymis protein 4 and renal fibrosis: A systemic review and 
meta-analysis. Medicine (Baltimore). 2017; 96 (36): e7824. 
19. Luo J, Wang F, Wan J et al. Serum human epididymis secretory protein 
4 as a potential biomarker of renal fibrosis in kidney transplantation 
recipients. Clin Chim Acta. 2018; 483: 216–221. 
20. Ren Y, Xie J, Lin F et al. Serum human epididymis protein 4 is a predictor 
for developing nephritis in patients with systemic lupus erythematosus: 
A prospective cohort study. Int Immunopharmacol. 2018; 60: 189–193. 
21. Yang Z, Zhang Z, Qin B et al. Human epididymis protein 4: a novel 
biomarker for lupus nephritis and chronic kidney disease in systemic 
lupus erythematosus. J Clin Lab Anal. 2016; 30 (6): 897–904. 
22. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 
2017; 67 (1): 7–30. 
23. Peng C, Liu G, Huang K et al. Hypoxia-induced upregulation of HE4 is 
responsible for resistance to radiation therapy of gastric cancer. Mol 
Ther Oncolytics. 2019; 12: 49–55. 
24. Kemal YN, Demirag GN, Bedir AM et al. Serum human epididymis 
protein 4 levels in colorectal cancer patients. Mol Clin Oncol. 2017; 7 
(3): 481–485. 
25. Lu Q, Chen H, Senkowski C et al. Recombinant HE4 protein promotes 
proliferation of pancreatic and endometrial cancer cell lines. Oncol 
Rep. 2016; 35 (1): 163–170. 
26. Mo D, He F. Serum human epididymis secretory protein 4 (HE4) is a 
potential prognostic biomarker in non-small cell lung cancer. Clin Lab. 
2018; 64 (9): 1421–1428. 
27. Celik B, Bulut T. Human epididymis protein 4 may not be a reliable 
screening biomarker for detecting lung carcinoma patients. Biomed 
Rep. 2017; 7 (4): 297–300. 
28. Korkmaz ET, Koksal D, Aksu F et al. Triple test with tumor markers CYFRA 
21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of 
lung cancer. Clin Biochem. 2018; 58: 15–19. 
29. Muley T, He Y, Rolny V et al. Potential for the blood-based biomarkers 
cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 
4 (HE4) to detect recurrence during monitoring after surgical resection 
of adenocarcinoma of the lung. Lung Cancer. 2019; 130: 194–200. 
30. Molina R, Barak V, van Dalen A et al. Tumor markers in breast cancer 
– European Group on Tumor Markers recommendations. Tumour Biol. 
2005; 26 (6): 281–293. 
31. Guo LJ, Zhang QY. Decreased serum miR-181a is a potential new tool 
for breast cancer screening. Int J Mol Med. 2012; 30 (3): 680–686.
32. Lu M, Ju S, Shen X et al. Combined detection of plasma miR-127-3p and 
HE4 improves the diagnostic efficacy of breast cancer. Cancer Biomark. 
2017; 18 (2): 143–148. 
33. Piek A, Du W, de Boer RA et al. Novel heart failure biomarkers: why do we 
fail to exploit their potential? Crit Rev Clin Lab Sci. 2018; 55 (4): 246–263. 
34. de Boer RA, Cao Q, Postmus D et al. The WAP four-disulfide core domain 
protein HE4: a novel biomarker for heart failure. JACC Heart Fail. 2013; 
1 (2): 164–169. 
